文献速递白血病淋巴瘤

奥加伊妥珠单抗联合低强度化疗治疗新诊断CD22阳性费城染色体阴性B细胞前体急性淋巴细胞白血病的老年患者

Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22+ Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia.
PubMed 文献 · J Clin Oncol · 2024-10-17

EWALL-INO为开放标签前瞻性多中心II期试验,纳入131例55岁及以上新诊断CD22阳性费城染色体阴性B细胞前体急性淋巴细胞白血病患者,采用奥加伊妥珠单抗联合低强度化疗方案。诱导2后90%达完全缓解或血小板未完全恢复的完全缓解,80%可测量残留病<10^-4,1年总生存率73.2%,结论支持奥加伊妥珠单抗用于老年患者一线方案。

要点

  • 诱导2后90%患者达完全缓解或血小板未完全恢复的完全缓解,80%可测量残留病<10^-4
  • 1年总生存率73.2%,无复发生存率66%,累积复发率25%
  • 仅记录到1例非致死性肝窦阻塞综合征

核心结论

  • 研究结果支持奥加伊妥珠单抗用于CD22阳性费城染色体阴性B细胞前体急性淋巴细胞白血病老年患者的一线方案。

研究设计与样本

  • EWALL-INO为开放标签前瞻性多中心II期试验(ClinicalTrials.gov标识符NCT03249870)。
  • 纳入55岁及以上新诊断CD22阳性费城染色体阴性B细胞前体急性淋巴细胞白血病患者131例,中位年龄68岁。
  • 方案包括预治疗期后第一诱导(长春新碱、地塞米松及3次奥加伊妥珠单抗注射:第1天0.8 mg/m2,第8天/第15天0.5 mg/m2),第二诱导(环磷酰胺、地塞米松及2次奥加伊妥珠单抗注射:第1天/第8天0.5 mg/m2)。
  • 缓解者接受最多6周期化疗巩固及18个月化疗维持,允许在3次巩固后行异基因移植。
  • 主要终点为1年总生存率。

主要发现

  • 2017年12月至2022年3月共纳入131例患者;第一诱导期间3例死亡(多器官衰竭2例、出血1例),第二诱导期间无死亡。
  • 诱导2后90%患者达完全缓解或血小板未完全恢复的完全缓解,80%患者可测量残留病<10^-4。
  • 在缓解者(n=119)中,47例复发,14例在完全缓解或血小板未完全恢复的完全缓解状态下死亡。
  • 1年总生存率、无复发生存率和累积复发率分别为73.2%、66%和25%。
  • 高危细胞遗传学和较低CD22表达(<70%)与较差总生存相关,高危细胞遗传学和可测量残留病≥10^-4均与较低无复发生存率和较高累积复发率相关;10例接受异基因移植的患者结局良好(2年总生存率/无复发生存率90%,无复发)。

关键数值与推荐

  • 第一诱导奥加伊妥珠单抗剂量:第1天0.8 mg/m2,第8天/第15天0.5 mg/m2。
  • 第二诱导奥加伊妥珠单抗剂量:第1天/第8天0.5 mg/m2。
  • 可测量残留病<10^-4者占80%;可测量残留病≥10^-4与较低无复发生存率和较高累积复发率相关。
  • CD22表达<70%与较差总生存相关。
  • 仅记录到1例非致死性肝窦阻塞综合征。

临床怎么用

  • 作者结论认为研究结果支持奥加伊妥珠单抗用于CD22阳性费城染色体阴性B细胞前体急性淋巴细胞白血病老年患者的一线方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The use of inotuzumab ozogamicin (InO), a conjugated anti-CD22 monoclonal antibody, is becoming a promising frontline treatment for older patients with ALL. PATIENTS AND METHODS: EWALL-INO is an open-label prospective multicenter phase II trial (ClinicalTrials.gov identifier: NCT03249870). Patients age 55 years and older with newly diagnosed CD22+ Philadelphia chromosome-negative (Ph-) B-cell precursor (BCP) ALL were eligible. After a prephase, a first induction consisting of vincristine, dexamethasone, and three injections of InO (0.8 mg/m2 day 1, 0.5 mg/m2 day 8/day 15) was followed by a second induction combining cyclophosphamide, dexamethasone, and two injections of InO (0.5 mg/m2 day 1/day 8). Responders received up to six cycles of chemotherapy consolidation and 18-month chemotherapy maintenance. Allotransplant was allowed after three consolidations. The primary end point was 1-year overall survival (OS). RESULTS: Between December 2017 and March 2022, 131 patients (median age 68 years) were included. Three patients died during induction 1 (n = 130), two from multiple organ failure and one from hemorrhage, and none during induction 2 (n = 120). After induction 2, 90% of the patients achieved complete remission (CR) or CR with incomplete platelet recovery (CRp) and 80% had measurable residual disease (MRD2) <10-4. Among responders (n = 119), 47 relapsed and 14 died in CR/CRp. One-year OS, relapse-free survival (RFS), and cumulative incidence of relapse (CIR) rates were 73.2%, 66%, and 25%, respectively. High-risk cytogenetics and lower CD22 expression (<70%) were associated with worse OS, while both high-risk cytogenetics and MRD2 ≥10-4 were associated with lower RFS and higher CIR. The 10 allotransplanted patients had very favorable outcomes (90% 2-year OS/RFS and no relapse). Only one nonfatal sinusoidal obstructive syndrome was documented during the study. CONCLUSION: Our results support InO's use in first-line regimens for older patients with CD22+ Ph- BCP-ALL.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Chevallier P, Leguay T, Delord M, et al. Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22+ Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia. J Clin Oncol. 2024. PMID: 39418626. doi:10.1200/JCO.24.00490

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。